Within the framework of its investigation initiated due to excessive pricing concerns, the European Commission has accepted Aspen’s commitments to reduce its prices for 6 off-patent cancer medicines by 73. The press release dated 10 February 2021 about the decision of the European Commission is available at https://ec.europa.eu/commission/presscorner/detail/en/ip_21_524